FindTrial
Sign In

A study to see if Ayurvedic medicines (Paneeya Kshara and Shamanoushadhis) can help people with stomach and intestine cancer.

AN OPEN LABEL SINGLE ARM CLINICAL STUDY TO EVALUATE THE EFFICACY OF PANEEYA KSHARA AND SHAMANOUSHADHIS IN THE MANAGEMENT OF GASTRO-INTESTINAL CANCER. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/110228
Enrollment
30
Registered
2026-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C269- Malignant neoplasm of ill-definedsites within the digestive system

Interventions

Intervention1: Nil: Nil

Sponsors

Dr PUJARI AISHWARYA YALLAPPA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects diagnosed with GIT Cancers with or without GIT Symptoms (Esophagus, Stomach, Small intestine, Large intestine, Rectum, and Anus) and accessories(Liver, Gallbladder, and Pancreas).

Exclusion criteria

Exclusion criteria: Subjects who are unable to consume oral medicines and are terminally ill. Subjects who are contra-indicated for PaneeyaKshara. Pregnant and lactating women. Subjects with systemic disorders that interfere with the course of treatment.

Design outcomes

Primary

MeasureTime frame
Symptom Relief & Quality of Life To see if Paneeya Kshara and Shamanoushadhis reduce common GIT cancer symptoms (like indigestion, pain, bloating, loss of appetite) and improve patient comfort. Disease Management To evaluate whether these Ayurvedic medicines help in controlling or slowing the progression of gastrointestinal cancer, based on the treatment principles of Gulma.Timepoint: Pre-test: On 0th day, Subjective and Objective parameters(Hb%, TC, DC, ESR, ) and Weight Mid test: 3-On every 15th day. All the Subjective parameters, except the WHO-QOL-BREF questionnairewill be assessed every 15 days (15th, 30th, 45th day) Post test: 61st day, Subjective and Objective parameters(Hb%, TC, DC, ESR, ) and Weight.—

Secondary

MeasureTime frame
Secondary outcomes include improvement in quality of life, changes in Agni and digestive parameters, nutritional status, hematological and biochemical profiles, assessment of associated symptoms, disease progression status, and evaluation of safety and tolerability of the intervention. Timepoint: Pre-test: On 0th day, Subjective and Objective parameters(Hb%, TC, DC, ESR, ) and Weight Mid test: 3-On every 15th day. All the Subjective parameters, except the WHO-QOL-BREF questionnairewill be assessed every 15 days (15th, 30th, 45th day) Post test: 61st day, Subjective and Objective parameters(Hb%, TC, DC, ESR, ) and Weight.—

Countries

India

Contacts

Public ContactDr Beena MD

JSS Ayurveda Medical College

drpbsreddy@yahoo.com9538367282

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026